Characteristics of prion-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent-detergent treated) for neonatal exchange transfusion

Vox Sanguinis

Volumn 101, Issue 1, 2011, Pages 28-34

  Hornsey, V S ^a   Casey, C ^b   Mccoll, K ^b   Young, H ^c   Drummond, O ^a   Mcmillan, L ^a   Morrison, A ^a   Prowse, C V ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b South East Scotland BTS ^*  (United Kingdom)

^c Clinical Laboratory   (United Kingdom)

Author keywords

Methylene blue treated plasma; Neonatal exchange units; OctaplasLG; Prion reduction

Indexed keywords

ADENINE; ADENOSINE TRIPHOSPHATE; ALPHA 2 ANTIPLASMIN; FIBRINOGEN; GLUCOSE; MANNITOL; METHYLENE BLUE; OCTAPLASLG; PLASMA PROTEIN; POTASSIUM; PROTEIN S; REAGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD FILTRATION; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; HEMOLYSIS; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RISK REDUCTION; VIRUS INACTIVATION;

2,3-DIPHOSPHOGLYCERATE; ADENOSINE TRIPHOSPHATE; ALPHA-2-ANTIPLASMIN; BLOOD PRESERVATION; BLOOD PROTEINS; DETERGENTS; DISINFECTION; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FIBRINOGEN; FILTRATION; HEMOLYSIS; HUMANS; INFANT, NEWBORN; METHYLENE BLUE; PLASMA EXCHANGE; POTASSIUM; PRIONS; SOLVENTS;

EID: 79958803612     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01456.x     Document Type: Article

References (32)

1. Gillies M, Chohan G, Llewelyn CA, et al.: A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions. Vox Sang 2009; 97:211-218
2. Peden A, McCardle L, Head MW, et al.: Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16:296-304
3. Brown P, Cervenáková L, McShane LM, et al.: Further studies of blood infectivity in an experimental model of transmissible spongiforn encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
4. Gregori L, McCombie N, Palmer D, et al.: Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364:529-531
5. Creutzfeldt-Jakob Disease. Joint UKBTS/NIBSC Professional Advisory Committee Position Statement. 11th March 2010.
6. Feeley D: Availability of imported fresh frozen plasma in Scotland. Scottish Executive Health Department 2006.
7. Gregori L, Lambert BC, Gurgel PV, et al.: Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006; 46:1152-1161
8. Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO). Summary of the Eighth Meeting 27 October 2009.
9. Cahill MR, Murphy T, Khan M, et al.: Phase I/II safety study of transfusion of prion-filtered red cell concentrates in transfusion-dependent patients. Vox Sang 2010; 99:174-176
10. Guidelines for the Blood Transfusion Services in the UK, 7th edn. London, The Stationery Office, 2005.
11. British Committee for Standards in Haematology: Transfusion guidelines for neonates and older children. Br J Haematol 2004; 124:433-453
12. Wiltshire M, Thomas S, Scott J, et al.: Prion reduction of red blood cells: impact on component quality. Transfusion 2010; 50:970-979
13. Luban NL, Strauss RG, Hume HA: Commentary on the safety of red cells preserved in extended-storage media for neonatal transfusions. Transfusion 1991; 31:229-235
14. Neisser-Svae A, Bailey A, Gregori L, et al.: Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG. Vox Sang 2009; 97:226-233
15. sc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97:219-225
16. Lawrie AS, Green L, Canciani MT, et al.: The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang 2010; 99:232-238
17. Guidleines on the use of irradiated blood components. Prepared by the BCSH blood transfusion task force.
18. Cookson P, Sutherland J, Cardigan R: A simple spectrophotometric method for the quantification of residual haemoglobin in platelet concentrates. Vox Sang 2004; 87:264-271
19. de Korte D, Kleine M, Korsten HGH, et al.: Prolonged maintenance of 2, 3-diphosphoglycerate acid and adenosine triphosphate in red blood cells during storage. Transfusion 2008; 48:1081-1089
20. Lagerberg JWM, Truijens-de Lange R, de Korte D, et al.: Altered processing of thawed red cells to improve the in vitro quality during postthaw storage at 4°C. Transfusion 2007; 47:2242-2249
21. Perrotta PL, Baril L, Tead C, et al.: Effects of methylene blue-treated plasma on red cells and stored platelet concentrates. Transfusion 1999; 39:63-69
22. Geiger TL, Pisciotto PT, Baril LL, et al.: The effect of solvent/detergent - treated plasma on red cells stored in vitro. Transfusion 1995; 35:487-492
23. Hall TL, Barnes A, Miller JR, et al.: Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion 1993; 33:606-609
24. Heaton WAL: Evaluation of posttransfusion recovery and survival of transfused red cells. Transfus Med Rev 1992; VI(3):153-169
25. Solheim BG, Bergerud UE, Kjeldsen-Kragh J, et al.: Improved blood preservation with 0.5CPD erythro-sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood. Vox Sang 1998; 74:168-175
26. Hornsey VS, Drummond O, Young D, et al.: A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11:31-36
27. Garwood M, Cardigan RA, Drummond O, et al.: The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003; 43:1238-1247
28. Schleef M, Strobel E, Dick A, et al.: Relationship between ABO and secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2004; 128:100-107
29. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines: Human plasma (pooled and treated for virus inactivation). European Pharmacopoeia 63 2009; 1646:4168-4170
30. Hellstern P, Sachse H, Schwinn H, et al.: Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992; 63:178-185
31. Burnouf T, Goubran HA, Radosevich M, et al.: Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals 2007; 35:349-353
32. Osselaer J-C, Debry C, Goffaux M, et al.: Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48:108-117